共 268 条
[1]
Dalal P(2009)Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection Ther Clin Risk Manag 5 139-149
[2]
Grafals M(2004)Immunosuppression: practice and trends Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 4 38-53
[3]
Chhabra D(2005)Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism Drug Metab Dispos 33 139-146
[4]
Gallon L(2004)The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants Drug Metab Dispos 32 775-778
[5]
Kaufman DB(2006)Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid Drug Metab Dispos 34 1539-1545
[6]
Shapiro R(2013)Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus Xenobiotica 43 229-235
[7]
Lucey MR(2006)Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine Drug Metab Dispos 34 261-266
[8]
CherikhR TB, Dyke DB, WS(2016)Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs Ther Drug Monit 38 S57-69
[9]
Picard N(2010)Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil Drug Metab Dispos 38 2210-2217
[10]
Ratanasavanh D(2018)Regression and genomic analyses on the association between dose-normalized mycophenolic acid exposure and absolute neutrophil count in steroid-free, de novo kidney transplant recipients Clin Drug Investig 38 1011-1022